Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 1998

View Archived Issues

Celsion and Duke University enter oncology alliance

Group C meningococcal conjugate vaccine shown safe and immunogenic in phase II

Another market introduction for cidofovir

More telomerase inhibitors added to the Geron pipeline

New agents for inhibiting EGF receptor-mediated abnormal cell growth

RCT reports new HLE inhibitors

Searle conducts AIDS research, identifies protease inhibitors

NeoRx begins phase I trial of Pretarget technology in lymphoma

Phase II trial data reported for levormeloxifene

AxyS enters agreement with Parke-Davis

Positive phase II results for GMK vaccine presented at NCI-EORTC meeting

Interim results from dose-escalating phase I/II trials of PRO-542 presented at Bio '98

TOBI efficacy maintained in longer term studies

CMB-401, an immunoconjugate for the targeted treatment of EOC

Anthracenedione analogue BBR-2778 moves to phase I testing

Lilly's continued focus in the area of postmenopausal syndrome and estrogen-related disorders

Selective 5-HT1F agonists claimed to be particularly useful for migraine, chronic pain

Safe and effective agents for diabetes and diabetic complications described by ADIR

Stem cell factor BLA scheduled for review by CBER advisory committee in late July

Cationic peptides exert selective antitumor activity against sensitive and resistant cell lines

Pharmacopeia acquires Molecular Simulations

First patients being treated with bombesin/GRP antagonist RC-3095

Schering-Plough initiates phase I with oral antithrombotic

Flavone acetic acid analogue suppresses tumor blood perfusion, patient study shows

Favorable early clinical trial results presented for AERx-delivered insulin at diabetes congress

Broadened use of Taxotere in breast cancer cleared by FDA

Enbrel BLA accepted for review and assigned priority review status

Pharmacokinetics and metabolism of TAT-59 investigated in animals